Tonix Pharmaceuticals is a specialty biopharmaceutical company focused on commercializing and developing drugs for CNS disorders, immunology, infectious diseases, and rare diseases. Tonix currently markets two product areas: TONMYA and a migraine franchise. TONMYA (cyclobenzaprine HCl sublingual tablets) is a non-opioid treatment for fibromyalgia in adults, FDA-approved in August 2025 and launched in November 2025 — the first new fibromyalgia drug in over 15 years. TONMYA is a sublingual formulation of cyclobenzaprine designed for bedtime dosing, targeting non-restorative sleep believed to drive fibromyalgia symptoms. The sublingual delivery bypasses first-pass liver metabolism, producing a distinct pharmacokinetic profile versus oral cyclobenzaprine. Tonix's migraine franchise consists of Zembrace SymTouch, a low-dose sumatriptan autoinjector (the only actively promoted branded sumatriptan autoinjector in the U.S.), and Tosymra, a sumatriptan nasal spray with rapid absorption. Tonix sells its products through a combined internal and contracted sales force of roughly 90 field reps, targeting rheumatology, primary care, pain management, and neurology physicians, with distribution through national wholesalers and specialty pharmacies. The migraine franchise provided Tonix with a commercial infrastructure — sales force, distribution, and market access — that it is now leveraging for the TONMYA launch. Beyond marketed products, Tonix has a broad pipeline funded through its own capital, government grants, and academic partnerships, including programs in MDD, acute stress disorder, Lyme disease prophylaxis, kidney transplant rejection, cocaine intoxication, Prader-Willi syndrome, and broad-spectrum antivirals.